VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Monday. The brokerage set a “sell” rating on the stock.

VNRX has been the topic of several other reports. D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a report on Thursday, February 6th. Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Performance

Shares of NYSE VNRX opened at $0.58 on Monday. The business’s 50 day moving average price is $0.61 and its 200-day moving average price is $0.65. The company has a market cap of $53.29 million, a price-to-earnings ratio of -1.60 and a beta of 1.20. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.10.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes purchased 174,764 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the acquisition, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Cameron John Reynolds bought 139,811 shares of VolitionRx stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 358,266 shares of company stock worth $204,212. 12.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On VolitionRx

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares in the last quarter. Ground Swell Capital LLC lifted its stake in VolitionRx by 78.8% during the third quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock worth $28,000 after purchasing an additional 20,249 shares in the last quarter. Millennium Management LLC acquired a new position in VolitionRx during the fourth quarter worth $36,000. Northern Trust Corp lifted its stake in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Finally, Lagoda Investment Management L.P. lifted its stake in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.